CTA
IART icon

Carillon Tower Advisers’s Integra LifeSciences IART Stock Holding History

Carillon Tower Advisers’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,300
Closed -$493 – 466
2017
Q4 		$493 Buy
+10,300
New +$504K 0.01% 285

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carillon Tower Advisers's IART Position: Q1 2018 in Review

Carillon Tower Advisers sold out of Integra LifeSciences (IART) in Q1 2018, closing a stake of 10,300 shares — an estimated $493 sold.

Carillon Tower Advisers first reported a position in IART in Q4 2017 and held it in 1 quarter. The position peaked at $493 in Q4 2017. 235 funds tracked by Wall St. Rank hold IART as of Q1 2018.

  • Carillon Tower Advisers reported no remaining Integra LifeSciences position as of Q1 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 10,300 Integra LifeSciences shares in Q1 2018, an estimated $493.
  • Carillon Tower Advisers first reported a position in Integra LifeSciences in Q4 2017 and held it in 1 quarter.
  • Carillon Tower Advisers's Integra LifeSciences position peaked at $493 in Q4 2017.
  • 235 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2018.

Based on Carillon Tower Advisers's 13F filing for Q1 2018, filed 14 May 2018.